Recursion Cash from 2010 to 2024
| RXRX Stock | USD 5.89 0.11 1.83% |
Cash | First Reported 2010-12-31 | Previous Quarter 391.6 M | Current Value 342.9 M | Quarterly Volatility 157 M |
Check Recursion Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Recursion Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 19.1 M, Interest Income of 19.2 M or Depreciation And Amortization of 25.6 M, as well as many indicators such as Price To Sales Ratio of 43.68, Dividend Yield of 0.0 or PTB Ratio of 4.64. Recursion financial statements analysis is a perfect complement when working with Recursion Pharmaceuticals Valuation or Volatility modules.
Recursion | Cash |
Latest Recursion Pharmaceuticals' Cash Growth Pattern
Below is the plot of the Cash of Recursion Pharmaceuticals over the last few years. Cash refers to the most liquid asset of Recursion Pharmaceuticals, which is listed under current asset account on Recursion Pharmaceuticals balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Recursion Pharmaceuticals customers. The amounts must be unrestricted with restricted cash listed in a different Recursion Pharmaceuticals account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. Recursion Pharmaceuticals' Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Recursion Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Cash | 10 Years Trend |
|
Cash |
| Timeline |
Recursion Cash Regression Statistics
| Arithmetic Mean | 168,696,096 | |
| Geometric Mean | 119,959,175 | |
| Coefficient Of Variation | 93.09 | |
| Mean Deviation | 131,750,795 | |
| Median | 69,883,000 | |
| Standard Deviation | 157,040,373 | |
| Sample Variance | 24661.7T | |
| Range | 480M | |
| R-Value | 0.78 | |
| Mean Square Error | 10359.1T | |
| R-Squared | 0.61 | |
| Significance | 0.0006 | |
| Slope | 27,424,872 | |
| Total Sum of Squares | 345263.5T |
Recursion Cash History
Other Fundumenentals of Recursion Pharmaceuticals
Recursion Pharmaceuticals Cash component correlations
Click cells to compare fundamentals
About Recursion Pharmaceuticals Financial Statements
Recursion Pharmaceuticals investors use historical fundamental indicators, such as Recursion Pharmaceuticals' Cash, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Recursion Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Recursion Stock Analysis
When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.